FY2030 Earnings Forecast for CNTX Issued By HC Wainwright

Context Therapeutics Inc. (NASDAQ:CNTX) – Research analysts at HC Wainwright decreased their FY2030 earnings per share estimates for shares of Context Therapeutics in a note issued to investors on Thursday, May 7th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of $0.06 for the year, down from their prior estimate of $0.08. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.49) per share.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.03.

Several other brokerages have also issued reports on CNTX. Guggenheim reiterated a “buy” rating and issued a $5.00 target price on shares of Context Therapeutics in a research report on Tuesday, March 24th. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Tuesday, March 24th. Wall Street Zen cut Context Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Piper Sandler boosted their target price on Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $6.60.

Context Therapeutics Price Performance

Shares of NASDAQ:CNTX opened at $2.31 on Friday. The company’s fifty day moving average price is $2.62 and its 200-day moving average price is $1.90. The firm has a market capitalization of $211.78 million, a price-to-earnings ratio of -5.48 and a beta of 1.57. Context Therapeutics has a one year low of $0.49 and a one year high of $3.62.

Institutional Trading of Context Therapeutics

Large investors have recently modified their holdings of the business. Sanctuary Advisors LLC purchased a new position in Context Therapeutics during the 1st quarter valued at about $51,000. Virtu Financial LLC purchased a new stake in Context Therapeutics in the 4th quarter worth approximately $43,000. XTX Topco Ltd grew its position in shares of Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after buying an additional 91,008 shares during the last quarter. Quadrature Capital Ltd purchased a new position in shares of Context Therapeutics during the fourth quarter valued at approximately $68,000. Finally, Millennium Management LLC purchased a new position in shares of Context Therapeutics during the fourth quarter valued at approximately $3,824,000. 14.03% of the stock is owned by institutional investors.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.